Prescribing pattern of proton pump inhibitors among patients visiting the outpatient general medicine clinic in a tertiary care teaching hospital in Nepal

Bijaya Basyal†
School of Pharmacy, Chitwan Medical College, Bharatpur, Nepal and
Department of Pharmacy, School of Health and Allied Sciences, Pokhara University, Pokhara, Nepal
Nirmal Raj Marasine†
School of Pharmacy, Chitwan Medical College, Bharatpur, Nepal and
Department of Pharmacy, Karnali College of Health Science, Kathmandu, Nepal
Sabina Sankhi
Department of Pharmacy, Modern Technical College, Lalitpur, Nepal
Rajendra Lamichhane
Department of Public Health, School of Health and Allied Sciences, Pokhara University, Pokhara, Nepal, and
Bipashwi Nath Uprety
School of Pharmacy, Chitwan Medical College, Bharatpur, Nepal

Abstract
Purpose – The purpose of this study is to evaluate the prescribing pattern of proton pump inhibitors (PPIs) in patients visiting the outpatient general medical clinic in a Tertiary Care Teaching Hospital.

Design/methodology/approach – A hospital-based cross-sectional study was conducted in 419 patients aged ≥18 years, visiting the outpatient general medicine clinic of a tertiary hospital and prescribed with at least one PPI, from July to September 2016 using a purposive sampling technique. Descriptive statistics were performed using IBM-SPSS 20.0 (IBM Corporation, Armonk, NY, USA).

Findings – Patients were mostly less than 30 years (30.78%) and female (58.95%). Pantoprazole was the most frequently prescribed PPIs (57.04%). The majority of PPIs were prescribed for acid peptic disorder (APD) (33.65%), followed by non-steroidal anti-inflammatory drugs (NSAIDs) prophylaxis (30.79%). Most of the PPIs were prescribed for twice-daily administration (68.26%). Nearly one-fourth (21.72%) of the patients presented with at least one additional medical condition, and almost all (99%) patients were receiving at least one additional drug along with PPIs.

© Bijaya Basyal, Nirmal Raj Marasine, Sabina Sankhi, Rajendra Lamichhane and Bipashwi Nath Uprety. Published in Journal of Health Research. Published by Emerald Publishing Limited. This article is published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of this article (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at http://creativecommons.org/licences/by/4.0/legalcode

The authors would like to thank Chitwan Medical College Teaching Hospital for providing support to conduct this study.

Disclosure: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

†indicates, these authors contributed equally to this work.
Originality/value – The study suggests that PPIs are frequently prescribed and their use has been extended to other conditions that in fact do not require acid anti-secretory therapy. Result has highlighted the need for an interdisciplinary collaboration between pharmacists and medical professionals for the rational use of PPIs and promotion of PPIs prescription from the National List of Essential Medicines.

Keywords General medicine clinic, Outpatient, Prescription pattern, Proton pump inhibitors, Tertiary care teaching hospital, Nepal

Paper type Research paper

Introduction

Proton pump inhibitors (PPIs) are a group of drugs that are most effective at suppressing gastric acid secretion. Omeprazole, Esomeprazole, Dexlansoprazole, Lansoprazole, Pantoprazole and Rabeprazole fall under this group of drugs, and at comparable doses, these have equivalent efficacies [1]. The United States Food and Drug Administration (USFDA) has approved the use of PPIs in adults for the healing of erosive esophagitis (EE), gastroesophageal reflux disease (GERD), Zollinger-Ellison Syndrome (ZES), duodenal ulcer (DUs), maintenance of healed EE, risk reduction of gastric ulcer associated with non-steroidal anti-inflammatory drugs (NSAIDs) and H. pylori eradication to reduce the risk of (DU) recurrence in combination with antibiotics. However, not all PPIs are approved for each indication [1]. For most of these indications, the recommended maximum duration of therapy is 4 to 8 weeks [2]. Other indications, considered as the appropriate off-label use of PPIs are heartburn/regurgitation, refractory heartburn, Barrett’s esophagus, non-variceal gastrointestinal (GI) bleeding, bleeding ulcers, prophylaxis of upper GI bleeding in critically ill, dyspepsia and esophageal strictures [3]. According to the International Classification of Disease, Ninth Edition, Clinical Modification (ICD-9-CM), epigastric and periumbilical abdominal pain are acceptable symptoms for PPI therapy for the possible minimal duration without continuation [4]. These conditions are being common medical problems, and PPIs have become the most widely prescribed medications globally [5].

The worldwide scenario of PPI prescription shows increasing use in both primary and secondary care. In the United Kingdom, the prescription for PPIs has doubled within five years [6]. In the year 2005, PPIs were the third most widely sold drug class in the United States, with annual sales of $13.9 billion [7]. A consistent increase in the volume of prescriptions for PPIs was also reported in Australia [8], Germany [9] and the United States [10]. In 2006, global expenditure on PPIs was £7 billion, whereas England itself comprised £425 million [6]. There is no clear reason for the increased utilization and cost of PPIs. It is not explainable solely by increased morbidity, new indications, or a decrease in alternative medication [9].

In Nepal, Omeprazole has been enlisted in the National List of Essential Medicines [11]. Other PPIs, which are relatively safer than Omeprazole with non-differentiable efficacy, are also being marketed and used in Nepal. Developing countries like Nepal should utilize the drugs optimally from the National List of Essential Medicines, which eventually results in reduced healthcare cost of the country along with enhanced rational use of medicine. Hence, the study of the extent of Omeprazole use can also suggest and help the responsible authorized body to develop and implement policies regarding the effective utilization of essential medicines. Furthermore, there is a dearth of literature explaining the extent and pattern of PPI utilization in Nepal, which necessitates the determination of the rationality of PPI use. Therefore, this study aimed to evaluate the prescription pattern of PPIs among patients visiting the outpatient general medical clinic of a tertiary care teaching hospital.

Methodology

Design

This was a hospital-based cross-sectional study.
**Population**
Patients aged ≥18 years of age of either gender visiting the outpatient general medicine clinic of Chitwan Medical College (Chitwan, Nepal) between July and September 2016, prescribed with at least one PPI were eligible to be included in the study. Pregnant or lactating mothers, patients with a psychiatric disorder, from other departments, and those unable to communicate and understand the Nepali language were excluded.

**Sample size**
A sample size of 419 was taken to study prescription patterns of PPIs using a purposive sampling method.

**Data collection**
The eligibility of patients consenting to participate in this study was assessed. All information was collected in a well-designed proforma, which included age, sex and diagnosis/chief complaints, prescribed PPIs along with dose, frequency, duration, quantity, any comorbidities and other co-prescribed medicines. Personal identifiable information about patients or prescribers was not collected.

**Data analysis**
Descriptive statistics were performed using IBM-SPSS 20.0 (IBM Corporation, Armonk, NY, USA). The variables were presented as the mean, standard deviation, frequency and their respective percentage.

**Ethics issue**
This study was approved by the institutional review committee of Chitwan Medical College (CMC/IRC/42).

**Results**
Of the total of 419 patients, more than half (247; 58.95%) were female. The age of the patients ranged from 18 to 86 years, with the Mean ± Standard deviation age 41.99 ± 17.58 years. The majority of patients were in age groups of less than 30 (129; 30.78) while 9 (2.14) were above 80 years, as shown in Table 1.

Of the 419 patients, the majority of PPIs were prescribed for acid peptic disorder (APD) (141, 33.65%), followed by NSAIDs prophylaxis (129, 30.79%). Likewise, 46 (10.98%) PPIs were prescribed for epigastric/periumbilical pain, and 103 (25.06%) PPIs were prescribed

| Characteristics | Categories | n (%) |
|-----------------|------------|-------|
| Gender          | Male       | 172 (41.05) |
|                 | Female     | 247 (58.95) |
| Age (years)     | <30        | 129 (30.78) |
|                 | (30–39)    | 88 (21.00) |
|                 | (40–49)    | 74 (17.66) |
|                 | (50–59)    | 39 (9.30) |
|                 | (60–69)    | 45 (10.73) |
|                 | 70–79      | 35 (8.35) |
|                 | 80+        | 9 (2.14) |

**Table 1.** Demographic characteristics of patients (n = 419)
neither with NSAIDs nor in patients having any symptoms related to APD, as shown in Table 2.

Pantoprazole was the most commonly prescribed PPI (239, 57.04%) followed by Esomeprazole (92, 21.96%) and Rabeprazole (85, 20.29%) while Lansoprazole was the least frequently prescribed PPI (3, 0.72%). Omeprazole, which was listed in the National List of Essential Medicines, was not prescribed in the study population. The doses of PPIs used in the study were 40 mg for Esomeprazole and Pantoprazole, 30 mg for Lansoprazole and 20 mg for Rabeprazole as shown in Table 3.

The majority of patients were prescribed to take PPIs twice-daily (286, 68.26%) followed by 109 (26.01%) once-daily while 24 (5.73%) once daily administrations for continuous therapy after completion of the twice-daily regimen. The frequency of daily PPI administration on different conditions requiring PPI therapy as per the prescription is shown in Table 4.

Of the 419 patients, only 4 (1.0%) patients were receiving a PPI exclusively, while 111 (26.5%) received two additional drugs besides PPI, followed by three (94, 22.4%), four (70, 16.7%), five (46, 11.0%) and six to eight (36, 8.6%), respectively, as shown in Table 5.

Among the patients enrolled in this study, 415 (99%) were concomitantly receiving one or more groups of drugs, as shown in Figure 1.

Discussion

Our study evaluated the prescribing pattern of PPIs in the outpatient general medicine clinic of tertiary care hospitals of Nepal over a period of three months among 419 patients. Most of the patients were female with an average age of ~42 years. Interestingly, female patients were found to be at higher risk of receiving an unjustified prescription of PPIs. This may be because women tend to consult physicians more often and sooner than men.

| Conditions                          | No. of patients | Patient % |
|-------------------------------------|-----------------|-----------|
| Acid peptic disorders (APD)         |                 |           |
| Duodenal ulcer                      | 2               | 0.48      |
| Duodenitis                          | 1               | 0.24      |
| Gastric ulcer                       | 5               | 1.19      |
| Gastritis                           | 37              | 8.83      |
| Gastroduodenitis                    | 4               | 0.95      |
| Gastroesophageal reflux disease (GERD)| 9     | 2.15      |
| Upper gastrointestinal (UGI) bleeding| 1           | 0.24      |
| Unspecified in prescription         | 82              | 19.57     |
| **Sub-total**                       | **141**         | **33.65** |
| Epigastric/periumbilical pain       | 46              | 10.98     |
| NSAIDs prophylaxis                  | 129             | 30.79     |
| Not specified in the prescription   | 103             | 24.58     |
| **Total**                           | **419**         | **100.00**|

Table 2. 
Indication of PPIs therapy

| Drug name      | Anatomical therapeutic classification (ATC) code | Dose(mg) | n (%)  |
|----------------|-----------------------------------------------|----------|--------|
| Pantoprazole   | A02BC02                                       | 40       | 239 (57.04) |
| Esomeprazole   | A02BC05                                       | 40       | 92 (21.96)  |
| Rabeprazole    | A02BC04                                       | 20       | 85 (20.29)  |
| Lansoprazole   | A02BC03                                       | 30       | 3 (0.72)    |

Table 3. 
PPI utilization
The study revealed that most of the frequent correct indications for PPIs were APD (33.65%) followed by NSAIDs prophylaxis (30.79%). The effective use of PPI in APDs is evidence-based, for which there is a well-defined duration of therapy with a specified dose [1]. Any NSAIDs may increase the risk of bleeding, but effects are not cumulative and decrease quickly after discontinuation of the treatment. PPIs have been indicated for long-term preventive treatment and have proven useful for short NSAID courses, and acetylsalicylic acid therapy, mainly in aged patients [6]. In this study, PPI was prescribed for neither definitive nor prophylaxis and symptomatic treatment in 24.58% of patients. The reason for the inadequate use of PPIs could be co-morbidities and co-medication. The indication of PPIs in this situation is unclear. The findings of this study are consistent with the findings of another study [12], which showed that 29.4% of patients received a prescription for treatment.

| Frequency of PPI administration | Conditions                       | Number of patients | Percent (%) |
|---------------------------------|----------------------------------|--------------------|-------------|
| Once-daily                      | Acid peptic disorders (APD)      | 5                  | 1.2         |
|                                 | Gastritis                        | 14                 | 3.3         |
|                                 | Epigastric/periumbilical pain    | 11                 | 2.6         |
|                                 | NSAIDs prophylaxis               | 38                 | 9.1         |
|                                 | Not specified in the prescription| 41                 | 9.8         |
| Twice daily                     | Duodenal ulcer                   | 2                  | 0.5         |
|                                 | Duodenitis                       | 1                  | 0.2         |
|                                 | Gastric ulcer                    | 2                  | 0.5         |
|                                 | Acid peptic disorders (APD)      | 19                 | 4.5         |
|                                 | Gastritis                        | 1                  | 0.2         |
|                                 | Gastroduodenitis                 | 9                  | 2.1         |
|                                 | Gastroesophageal reflux disease (GERD) | 1          | 0.2         |
|                                 | Upper gastrointestinal (UGI) bleeding | 64               | 15.3       |
|                                 | Unspecified in prescription      | 35                 | 8.4         |
|                                 | NSAIDs prophylaxis               | 91                 | 21.7        |
|                                 | Not specified in the prescription| 61                 | 14.6        |
| Both*                           | Acid peptic disorders (APD)      | 3                  | 0.7         |
|                                 | Gastric ulcer                    | 13                 | 3.1         |
|                                 | Gastroduodenitis                 | 3                  | 0.7         |
|                                 | Unspecified in prescription      | 4                  | 1.0         |
|                                 | Not specified in the prescription| 1                  | 0.2         |
| Total                           |                                  | 419                | 100.0       |

Note(s): *This includes once-daily administration of PPI after completion of twice-daily administration of PPI.

| Additional drugs | No. of patients | Percentage (%) |
|------------------|-----------------|----------------|
| 0                | 4               | 1.0            |
| 1                | 58              | 13.8           |
| 2                | 111             | 26.5           |
| 3                | 94              | 22.4           |
| 4                | 70              | 16.7           |
| 5                | 46              | 11.0           |
| 6 or more        | 36              | 8.6            |
| Total            | 419             | 100.0          |

Table 4. Frequency of daily PPIs administration on different conditions requiring PPI prescription as per the prescription

Table 5. Number of additional medicines per prescription
of APD, 11.4% of patients received symptomatic relief, and 49.8% of patients received NSAIDs prophylaxis, while 9.4% of prescriptions were for other reasons, which are less than that of our study.

All five PPIs are effective and safe; however, there are differences in PPIs pharmacokinetic and pharmacodynamics profiles that might influence their clinical efficacy [8]. Our study revealed that more than half of the patients (57.04%) were treated with Pantoprazole, while about the same number (21.96% and 20.29%, respectively) received Esomeprazole and Rabeprazole, and only a few received Lansoprazole. Although Omeprazole is listed in the National List of Essential Medicines of Nepal, no one in the studied population was prescribed Omeprazole. In contrast to these findings, different studies reported that the majority of patients were treated with Omeprazole, while only a small group received other PPIs [4, 13].

Our study showed that the majority of patients (68.25%) were prescribed PPIs for twice-daily administration, while among this 5.73% of the patients were recommended to switch twice-daily therapy to once-daily therapy after completion of twice-daily therapy for a certain period. In (4.53%) patients, once-daily therapy was continued for maintenance of healed condition after completion of triple-drug therapy used for *H. pylori* eradication. A study from India showed that the frequency of PPI administration was once daily in most of the patients.
The duration of therapy with PPI cannot be commented on since the duration of therapy varied between the patients with the same diagnosed condition.

Our study revealed a high prevalence of patients receiving multiple medications prescribed PPIs, except in only 1% of the patients. In most of the patients (26.5%), two additional drugs were prescribed along with a PPI. Up to three additional drugs were prescribed for 62.7% of patients, which explains the use of multiple drugs in patients, with approximately one-third (36.3%) of patients being prescribed more than three additional drugs. The pattern of concomitant prescription of drugs with PPI in this study differs from that of another study [14], where PPIs were prescribed exclusively in 21.2% of patients and most of the patients (31.9%) received a prescription with one additional drug with the use of more than three additional drugs in 6.1% of the patients.

There are some limitations to our study. This was a single-centered study conducted in a single center of the central part of Nepal in a relatively small sample size. Therefore, the generalizability of the findings remains to be explored. Ideally, patients should have to undergo an endoscopy to verify the diagnosis, but this study could not cover it, which is the other major limitation of the study. Determining indication depending on the prescription alone was a potential bias because it is possible that sometimes the prescription might have been justified by the physician during the patient assessment but was not documented in the prescription. However, the data on PPI use could be particularly useful for policy formulation of PPIs in Nepal.

Conclusion

Our study suggests that PPIs are frequently prescribed in patients visiting the outpatient general medicine clinic of central Nepal. The use of PPIs has been extended to other conditions that generally do not require acid anti-secretory therapy. These should be used only when there is documented evidence of a GI disorder that cannot be treated with an H2-receptor antagonist and where a PPI use is clinically justified. Moreover, there should be increased interdisciplinary collaboration between pharmacists and medical professionals for the rational use of PPIs, and prescribing PPIs from the National List of Essential Medicines should also be promoted.

References

1. Wallace JL, Sharkey KA. Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. In: Brunton LL, Chabner BA, Knollmann BC (Eds). Goodman and Gilman's: the pharmacological basis of therapeutics. 12th ed. New York, NY: McGraw-Hill Medical; 2011. p. 1309-22.

2. Atkins AM, Chandra Sekar RM. Proton pump inhibitors: their misuse, overuse, and abuse. IOSR J Pharm. 2013; 3(2): 25-9.

3. Boparai V, Rajagopalan J, Triadafilopoulos G. Guide to the use of proton pump inhibitors in adult patients. Drugs. 2008; 68(7): 925-47. doi: 10.2165/00003495-200868070-00004.

4. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care. 2010; 16(9): e228-34.

5. Haroon M, Yasin F, Gardezi SK, Adee F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep. 2013; 4(8): 2042533313497183. doi: 10.1177/2042533313497183.

6. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008; 336(7634): 2-3. doi: 10.1136/bmj.39406.449456.BE.

7. Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J. 2012; 105(11): 613-8. doi: 10.1097/SMJ.0b013e31826efbea.
8. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump inhibitors use in Australia. Pharm Drug Saf. 2010; 19(10): 1019-24. doi: 10.1002/pds.1969.

9. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol. 2010; 66(12): 1265-71. doi: 10.1007/s00228-010-0871-9.

10. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PloS One. 2013; 8(2): e56060. doi: 10.1371/journal.pone.0056060.

11. Ministry of Health and Population, Government of Nepal, Department of Drug Administration [DDA]. National list of essential medicines Nepal. [cited 2020 Sep 18]. Available at: http://www.dda.gov.np/content/essential-drug-list.

12. Levy-Neumand O, Carniaux F, Bonaz B, Durand A, Roblin X. Proton pump inhibitors in general medicine. Comparison of routine practices with marketing authorization indications. Gastroenterol Clin Biol. 2007; 31(1): 78-83. doi: 10.1016/s0399-8320(07)89330-4.

13. Machado-Alba J, Fernández A, Castrillón JD, Campo CF, Echeverri LF, Gaviria A, et al. Prescribing patterns and economic costs of proton pump inhibitors in Colombia. Colomb Med (Cali). 2013; 44(1): 13-8.

14. Nousheen, Tadvi NA, Shareef SM. Use of proton pump inhibitors in general practice: is it rationale? Int J Med Res Health Sci. 2014; 3(1): 37-42.

**Corresponding author**

Nirmal Raj Marasine can be contacted at: nirmalarasine@gmail.com